Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-021 in neovascular wet age-related macular degeneration
NCT02450981Phase 1Withdrawn
- Sponsor
- BIOCAD
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab biosimilar BCD-021 in neovascular age-related macular degeneration (NVAMD), sponsored by BIOCAD. Primary endpoint: Frequency of ocular and systemic Adverse Events and Serious Adverse Events at 85 days. Status: withdrawn.
02
Drugs
bevacizumab biosimilar BCD-021
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02450981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450981.